# Achieve Life Sciences (formerly OncoGenex)

Source: https://onco.cc/companies/achieve-life-sciences/  
OnCo record `achieve-life-sciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Achieve Life Sciences carries the trial record of OncoGenex, whose antisense drug custirsen failed phase 3 trials in prostate and lung cancer before the company turned to a smoking-cessation medicine.

## Summary

OncoGenex Pharmaceuticals, founded in 2000 in Bothell, Washington, developed custirsen (OGX-011), an antisense inhibitor of clusterin, and led the phase 3 SYNERGY and AFFINITY trials in metastatic castration-resistant prostate cancer and a phase 3 trial in non-small cell lung cancer, none of which improved survival. In 2017 it merged with Achieve Life Sciences, which now develops cytisinicline for smoking cessation, a cancer prevention aim. The custirsen trials sit on ClinicalTrials.gov under the Achieve name.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Achieve Life Sciences, Inc.; OncoGenex Pharmaceuticals; OncoGenex
- Tags: ctgov-sponsor
- HQ: Bothell, WA
- Type: biotech
- Website: https://www.achievelifesciences.com

## Sources

- Official website: https://www.achievelifesciences.com
- ClinicalTrials.gov: trials led by Achieve Life Sciences, Inc.: https://clinicaltrials.gov/search?lead=Achieve%20Life%20Sciences%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q30269222

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/)

---
JSON: https://onco.cc/api/v1/entities/achieve-life-sciences.json